TAKOTSUBO CARDIOMYOPATHY IN THE SETTING OF COVID-19
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2021.1.12099Keywords:
stress cardiomyopathy, Takotsubo syndrome, COVID-19, SARS-COV-2Abstract
Summary. It is anticipated that as the number of COVID-19 cases rises worldwide, there will be an increase in the number of associated cardiovascular complications, and Takotsubo syndrome is one of them. Clinicians should be aware of the diversity of cardiovascular complications and should strategize appropriately for diagnosing and managing them.
The aim of the study – to analyze the literature on the features of Takotsubo syndrome in COVID-19 pandemic.
Materials and Methods. The study looked at scientific publications over the last decade that are available on the Internet, with the keywords “Stress cardiomyopathy”, “Takotsubo syndrome”, “COVID-19″.
Results. As COVID-19 pandemic progresses globally, a clear picture of cardiovascular manifestation and associated complications is emerging. The reports in the literature illustrate various cardiovascular complications of COVID-19 infection, including acute myocardial infarction, myocarditis, cardiomyopathy, arrhythmias and venous thromboembolism. Information on Takotsubo cardiomyopathy as a complication of COVID-19 is based on the results of studies with relatively limited number of case reports and case series. Patients with COVID-19 have been shown to have elevated levels of proinflammatory cytokines. The cytokine storm brought about by overwhelming systemic COVID-19 disease can be the physical and chemical stressor. Furthermore, studies also reported an increased incidence of development of stress cardiomyopathy due to COVID-19 pandemic in COVID-19-negative patients suggesting a key role for psychological distress in its development.
Conclusions. The correlation between the SARS-CoV-2 virus pandemic and the development of stress cardiomyopathy is undeniable. In some cases, it is a cardiac manifestation of infectious disease is triggered by Coronavirus SARS-CoV-2, in other situations it is the result of increased anxiety and stress due to COVID-19 pandemic.
References
Oryshchyn ND, Ivaniv YA [Cardiovascular complications in COVID-19: case report and concise review]. Proc Shevchenko Sci Soc Med Sci. 2020;62(2): 87-98. Ukrainian.
Suspitsyna IN, Sukmanova IA [Takotsubo syndrome. Clinical and pathogenetic aspects. Basics of diagnosis and treatment]. Kardiologiya. 2020;60(2): 96-103. Russian.
Shlyakhto EV, Parmon EV, Berngardt ER, Zhabina ES [Features of electrocardiographic changes in non-coronarogenic syndromes in patients with COVID-19]. Ros Card J. 2020;25(7): 194-00. Russian.
Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal. 2018;39(22): 2032-46.
Schultz T, Shao Y, Redfors B, Bergmann Sverrisdóttir Y, Råmunddal T, Albertsson P et al. Stress-Induced Cardiomyopathy in Sweden: Evidence for Different Ethnic Predisposition and Altered Cardio-Circulatory Status. Cardiology. 2012;122(3): 180-6.
Wittstein IS. Stress cardiomyopathy: A syndrome of catecholamine mediated myocardial stunning? Cellular and Molecular Neurobiology. 2012;32(5): 847-57.
Redfors B, Vedad R, Angerås O, Råmunddal T, Petursson P, Haraldsson I et al. Mortality in takotsubo syndrome is similar to mortality in myocardial infarction — A report from the SWEDEHEART registry. International Journal of Cardiology. 2015;185: 282-9.
Madias JE. Why the current diagnostic criteria of Takotsubo syndrome are outmoded: A proposal for new criteria. International Journal of Cardiology. 2014;174(3): 468-70.
Parodi G, Citro R, Bellandi B, Provenza G, Marrani M, Bossone E. Revised clinical diagnostic criteria for Tako-tsubo syndrome: The Takotsubo Italian Network proposal. International Journal of Cardiology. 2014;172(1): 282-3.
Prasad A, Dangas G, Srinivasan M, Yu J, Gersh BJ, Mehran R et al. Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: An analysis from a multicenter, international study of ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions. 2014;83(3): 343-8.
Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology: Current state of knowledge on Takotsubo syndrome. European Journal of Heart Failure. 2016;18(1): 8-27.
Aizawa K, Suzuki T. Takotsubo Cardiomyopathy: Japanese perspective. Heart Failure Clinics. 2013;9(2): 243-7.
Staedtke V, Bai R-Y, Kim K, Darvas M, Davila ML, Riggins GJ, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564: 273-7.
Shilova AS, Shmotkina AO, Yafarova AA, Gilyarov MYu [Takotsubo syndrome: Contemporary views on the pathogenesis, prevalence and prognosis]. Rats farmakot v kardiol. 2018;14(4): 598-04. Russian
Husam M Salah, Jawahar L Mehta Takotsubo cardiomyopathy and COVID-19 infection. European Heart Journal – Cardiovascular Imaging. 2020;21: 1299-300.
Gomez J, Nair G, Nanavaty P, Rao A, Marinescu K, Suboc T. COVID-19-associated takotsubo cardiomyopathy BMJ Case Rep 2020;13: 236-40.
Delmas C, Lairez O, Mulin E, Delmas T, Boudou N, Dumonteil N, Biendel-Picquet C, Roncalli J, Elbaz M, Galinier M, Carrié D. Anxiodepressive disorders and chronic psychological stress are associated with Tako-Tsubo cardiomyopathy – new physiopathological hypothesis. Circ. J. 2013;77: 175-80.
Jabri A, Kalra A, Kumar A, et al., Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic, JAMA Network Open. 2020;3(7); e2014780.
Giavarini A, Chedid A, Bobrie G, Plouin P-F, Hagège A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart. 2013;99(19): 1438-44.
Finsterer J, Wahbi K. CNS disease triggering Takotsubo stress cardiomyopathy. International Journal of Cardiology. 2014;177(2): 322-9.
Suzuki H, Matsumoto Y, Kaneta T, Sugimura K, Takahashi J, Fukumoto Y et al. Evidence for Brain Activation in Patients with Takotsubo Cardiomyopathy. Circulation Journal. 2014;78: 256-8.
Martens G, Gerritsen L, Duijndam S, Salemink E, Engelhard I, et al. Fear of Corona Virus (COVID-19): predictors in an online study conducted in March 2020, J. Anxiety Disord. Available from: https://doi.org/10.1016/j.janxdis.2020.102258.
Meyer P, Degrauwe S, Van Delden C, et al. Typical takotsubo syndrome triggered by SARSCoV-2 infection. Eur Heart J. 2020;41(19): 1860.
Minhas A, Scheel P, Garibaldi B. Takotsubo syndrome in the setting of COVID-19. JACC Case Rep. 2020. 2(9): 1321-5.
Ghadri J, Wittstein I, Prasad A. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018;39(22): 2032-46.
Desai HD, Sharma K, Jadeja DM, Desai HM, Moliya P. COVID-19 pandemic induced stress cardiomyopathy: a literature review. Int J Cardiol Heart Vasc. 2020;31: 100628.
Penefsky ZJ, Kahn M. Inotropic effects of dexamethasone in mammalian heart muscle. Eur J Pharmacol. 1971;15: 259-66.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Bulletin of Medical and Biological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
